Preclinical Efficacy Testing of New Drug Candidates

被引：48
|
作者：
Nuermberger, Eric L. [1 ,2 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD 21231 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21231 USA
来源：
MICROBIOLOGY SPECTRUM | 2017年 / 5卷 / 03期
关键词：
MYCOBACTERIUM-TUBERCULOSIS INFECTION; MULTIDRUG-RESISTANT TUBERCULOSIS; FIBER SYSTEM MODEL; MOXIFLOXACIN-CONTAINING REGIMENS; EARLY BACTERICIDAL ACTIVITY; GUINEA-PIG MODEL; MOUSE MODEL; STERILIZING ACTIVITY; LATENT TUBERCULOSIS; RABBIT MODEL;
D O I：
10.1128/microbiolspec.TBTB2-0034-2017
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
This is a review of the preclinical efficacy testing of new antituberculosis drug candidates. It describes existing dynamic in vitro and in vivo models of antituberculosis chemotherapy and their utility in preclinical evaluations of promising new drugs and combination regimens, with an effort to highlight recent developments. Emphasis is given to the integration of quantitative pharmacokinetic/pharmacodynamic analyses and the impact of lesion pathology on drug efficacy. Discussion also includes in vivo models of chemotherapy of latent tuberculosis infection.
引用
收藏
页数：22
相关论文
共 50 条
  • [41] Preclinical experiences with magnetic drug targeting: Tolerance and efficacy
    Lubbe, AS
    Bergemann, C
    Huhnt, W
    Fricke, T
    Riess, H
    Brock, JW
    Huhn, D
    CANCER RESEARCH, 1996, 56 (20) : 4694 - 4701
  • [42] Understanding the Preclinical Efficacy of Antibody-Drug Conjugates
    Diaz-Tejeiro, Cristina
    de Sa, Alfonso Lopez
    Poyatos-Racionero, Elisa
    Ballestin, Pablo
    Bartolome, Jorge
    Calvo, Emiliano
    Moreno, Victor
    Moris, Francisco
    Perez-Segura, Pedro
    Gyorffy, Balazs
    Pandiella, Atanasio
    Ocana, Alberto
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (23)
  • [43] An integrated process for measuring the physicochemical properties of drug candidates in a preclinical discovery environment
    Kibbey, CE
    Poole, SK
    Robinson, B
    Jackson, JD
    Durham, D
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (08) : 1164 - 1175
  • [44] Exciting challenges in the regulatory field of preclinical abuse liability testing of novel CNS-active drug candidates: can we cope?
    Teuns, G.
    TOXICOLOGY LETTERS, 2018, 295 : S44 - S44
  • [45] Preclinical Drug Efficacy and Safety Using NMR Spectroscopy
    Coen, Muireann
    Wilson, Ian D.
    EMAGRES, 2015, 4 (02): : 277 - 287
  • [46] Testing candidate topical microbicides - Distinguishing toxicity from efficacy in preclinical testing
    Beer, Brigitte
    Cummins, James
    Reichelderfer, Patricia
    Lackman-Smith, Carol
    RETROVIROLOGY, 2005, 2 (Suppl 1)
  • [47] Testing Candidate Topical Microbicides – Distinguishing Toxicity from Efficacy in Preclinical Testing
    Brigitte Beer
    James Cummins
    Patricia Reichelderfer
    Carol Lackman-Smith
    Retrovirology, 2
  • [48] The Selection and Testing of New Candidates for an Apple Pollinizer
    Shen, Xiang
    Li, Xin
    Hu, Yanli
    Guo, Ling
    Zhang, Donglin
    HORTSCIENCE, 2012, 47 (09) : S312 - S312
  • [49] Selection of HIV vaccine candidates for concurrent testing in an efficacy trial
    Huang, Ying
    DiazGranados, Carlos
    Janes, Holly
    Huang, Yunda
    deCamp, Allan C.
    Metch, Barbara
    Grant, Shannon
    Sanchez, Brittany
    Phogat, Sanjay
    Koutsoukos, Marguerite
    Kanesa-Thasan, Niranjan
    Bourguignon, Patricia
    Collard, Alix
    Buchbinder, Susan
    Tomaras, Georgia D.
    McElrath, Julie
    Gray, Glenda
    Kublin, James G.
    Corey, Lawrence
    Gilbert, Peter B.
    CURRENT OPINION IN VIROLOGY, 2016, 17 : 57 - 65
  • [50] Novel tools for drug efficacy testing
    Ignatiadis, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 68 - 68
12345